Bitcoin price today: slips below $113k, near 6-wk low despite Fed cut bets
On Monday, Stifel analysts reiterated their Buy rating for Arcellx Inc. (NASDAQ: ACLX) with a consistent price target of $122.00. Currently trading at $64.01, the stock has significant upside potential according to analyst consensus, with targets ranging from $104 to $134. According to InvestingPro data, the company maintains a "GOOD" overall financial health score of 2.84. Their position follows discussions at the NYC Biotech Doc Days event, where Dr. Mateo Mejia Saldarriaga from Weill Cornell and Dr. Jae Park from MSK shared their insights on Multiple Myeloma and BCMA-CAR-T therapies.
The analysts highlighted that the medical experts expressed limited enthusiasm for cilta-cel as a second-line treatment, citing concerns about Parkinsonism, a rare but serious side effect that could tilt the risk/benefit balance in favor of other treatments. This sentiment is seen as potentially beneficial for Arcellx's anito-cel, which may gain market adoption due to its more favorable toxicity profile. The company's strong balance sheet, with more cash than debt and a healthy current ratio of 4.29, positions it well to support continued development and potential commercialization.
Moreover, the panel's positive reception of the recent ASH 2024 data on anito-cel was noted. However, despite the lack of Parkinsonism cases in the iMMagine-1 study, which has been viewed favorably, there remains skepticism among some investors. Concerns revolve around the limited follow-up data and the possibility that future cases of Parkinsonism could emerge, potentially impacting the stock negatively.
Stifel suggests that additional data, which may be presented at upcoming conferences like ASCO, could bolster confidence in anito-cel's safety profile and act as a catalyst for Arcellx stock. The firm believes that further evidence supporting the treatment's safety could drive conviction among investors and positively influence the stock's performance. While the stock has experienced a -17.86% YTD return, InvestingPro analysis reveals 8 additional investment insights and detailed valuation metrics available to subscribers, including comprehensive Fair Value analysis and growth potential indicators.
In other recent news, Arcellx Inc. has been the subject of several recent analyst notes. Stifel has maintained its Buy rating on Arcellx, highlighting the potential of the company's candidate, anito-cel, in the Multiple Myeloma market. TD Cowen also maintained a Buy rating, citing the potential of anito-cel and its superior safety profile. BofA Securities increased its price target for Arcellx shares and continued its Buy rating based on positive developments in the company's anito-cel therapy. Truist Securities raised its price target for Arcellx and reaffirmed its Buy rating, citing the company's strong financial position and promising data for Anito-cel. Finally, Piper Sandler maintained an Overweight rating on Arcellx and raised its price target, following the company's third-quarter 2024 earnings report and upcoming presentations at the American Society of Hematology meeting. These are all recent developments in the company's progress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.